Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line platinum-based chemotherapy followed by maintenance treatment for advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer: SMC2799
A Management Information Statistics publication for Scotland
- Published
- 24 June 2025 (Latest release)
- Type
- Statistical report
- Author
- Public Health Scotland
About this release
This release by Public Health Scotland (PHS) uses information from the National SACT dataset.
The aim of this work was to capture real-world evidence from Scotland on the use of maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) Systemic Anti-Cancer Therapy (SACT) of adult patients with advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, following completion of first-line platinum-based chemotherapy.
The Scottish Medicines Consortium (SMC) requested this work which describes current SACT use in this population. This work will assist SMC members when considering submissions for rucaparib (SMC2799).
The objectives of this work were to:
- Determine the number of patients who received maintenance PARPi treatment for advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer following completion of first-line platinum-based chemotherapy, and details of the regimens used.
- Describe baseline characteristics of patients who received maintenance PARPi treatment for advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.
- Provide information on SACT used prior to maintenance treatment for advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Main points
- This report provides baseline characteristics of the 451 patients prescribed PARPi for treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer within 12 weeks of completion of first-line platinum-based chemotherapy which started between 1st July 2021 and 30th June 2024.
- The median age of patients was 67 years (Interquartile range 59-74) and most patients (n=388, 86.0%) had an ECOG Performance status of 0-1.
- Most patients (n=329, 72.9%) were prescribed niraparib as maintenance treatment after platinum-based SACT. Olaparib (n=105, 23.3%) and olaparib in combination with bevacizumab (n=17, 3.8%) were also used.
- Most patients (n=303, 67.2%) received carboplatin + paclitaxel or single agent carboplatin (n=99, 22%) as first line platinum-based chemotherapy, prior to maintenance PARPi.
| Characteristic | Number of patients (%) (N=451) |
|---|---|
| Treatment location | |
| WoSCAN | 215 (47.7%) |
| NCA | 118 (26.2%) |
| SCAN | 118 (26.2%) |
| Age [years] | |
| Median (IQR) | 67 (59 - 74) |
| Sex | |
| Female | 451 (100.0%) |
| Maintenance treatment | |
| Niraparib | 329 (72.9%) |
| Olaparib | 105 (23.3%) |
| Olaparib + bevacizumab | 17 (3.8%) |
| Platinum Containing Regimen Prescribed Prior to Maintenance Treatment | |
| Carboplatin + paclitaxel | 303 (67.2%) |
| Carboplatin | 99 (22%) |
| Carboplatin + paclitaxel + bevacizumab | 21 (4.7%) |
| Carboplatin + nab-paclitaxel | 20 (4.4%) |
| Other1 | 8 (1.7%) |
| Eastern Cooperative Oncology Group Performance Status (ECOG PS) | |
| 0 | 172 (38.1%) |
| 1 | 216 (47.9%) |
| 2+ | 26 (5.8%) |
| Unknown | 37 (8.2%) |
| Scottish Index of Multiple Deprivation (SIMD)2 | |
| 1 (most deprived) | 63 (14.0%) |
| 2 | 80 (17.7%) |
| 3 | 91 (20.2%) |
| 4 | 105 (23.3%) |
| 5 (least deprived) | 108 (23.9%) |
| Unknown | 4 (0.9%) |
KEY: WoSCAN - West of Scotland Cancer Network; NCA - North Cancer Alliance; SCAN - South East Cancer Network.
1Includes the following regimens: Carboplatin + docetaxel; carboplatin + liposomal doxorubicin; and cisplatin
2Using SIMD 2020 definition.
Cancer Medicines Outcome Programme (CMOP) Background
The overall vision of the Cancer Medicines Outcomes Programme-Public Health Scotland (CMOP-PHS) collaboration is to better understand the real-life impact of cancer medicines on cancer patients in Scotland. Healthcare professionals may then use these findings to help support clinical decision making and enable a more bespoke and individualised approach to the provision of cancer care for all our patients. Developing, and refining, a robust and reliable process means that cancer medicines intelligence may be routinely generated to support informed decision making at individual, local, and national levels.
Together with information available from clinical trials, this additional knowledge is intended to help NHS Scotland deliver a more personalised approach to providing cancer care, and to help ensure the safe and effective use of medicines.
The CMOP-PHS collaboration builds on established clinical engagement across NHS Scotland Health Boards and integrates with key stakeholders, thereby bringing together clinical, academic and data analysis skills from the NHS, Public Health Scotland, and academia, alongside the patient and public voice. The collaboration provides organisational memory and supports workforce resilience, embedding robust processes to routinely generate and report real-world evidence (RWE). This supports the provision of patient-centred cancer care and decision-making processes, setting Scotland apart as a centre of excellence in the cancer medicines RWE arena.
Scottish Medicines Consortium
The Scottish medicines Consortium (SMC) considers a broad range of evidence to decide which medicines should be accepted for use nationally by NHSScotland. The committee is made up of clinicians, pharmacists, NHS board representatives, the pharmaceutical industry and the public. More information can be found here.
This report will be used by the New Drugs Committee (NDC) in their assessment of rucaparib as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. (SMC2799). Once reviewed by SMC advice will be published via their website.
General enquiries
If you have an enquiry relating to this publication, please email phs.cmop@phs.scot.
Media enquiries
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email phs.otherformats@phs.scot.
To report any issues with a publication, please email phs.generalpublications@phs.scot.
Older versions of this publication
Versions of this publication released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.